This site is intended for US
healthcare professionals only.

Important Safety Information Prescribing Information

TREATING MYELOMA CAN SEEM LIKE A MARATHON

WOULD YOU TAKE OFF YOUR SHOE WHEN RUNNING A MARATHON?

Continuous treatment with a proteasome inhibitor (PI)–based regimen is associated with clinical benefits.1 However, most patients who have had 1 prior therapy only receive PIs for 4 to 7 months.21-23

The NINLARO® (ixazomib) regimen extended PFS by ~6 months (median: 20.6 vs 14.7 months) vs placebo regimen in patients with multiple myeloma who have received at least 1 prior therapy.1*†

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

SEE THE PATH TO EXTENDED PFS
VIEW SAFETY